Efficacy of Janus kinase inhibitors in rheumatoid arthritis

被引：0
|
作者：
Camille Langbour
Jessica Rene
Philippe Goupille
Guillermo Carvajal Alegria
机构：
[1] CHRU de Tours,Service de Rhumatologie
[2] Université de Tours,undefined
来源：
Inflammation Research | 2023年 / 72卷
关键词：
Tofacitinib; Upadacitinib; Baricitinib; Filgotinib; Rheumatoid arthritis; Efficacy; Predictive factors;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1121 / 1132
页数：11
相关论文
共 50 条
  • [21] Drug efficacy and safety of biologics and Janus kinase inhibitors in elderly patients with rheumatoid arthritis
    Ebina, Kosuke
    MODERN RHEUMATOLOGY, 2022, 32 (02) : 256 - 262
  • [22] Frequency of Prescription Claims for Drugs that May Interact with Janus Kinase Inhibitors Among Patients with Rheumatoid Arthritis in the US
    Alison Walton
    Jim Paik
    Amanda Quebe
    Carol L. Kannowski
    Casey Choong
    Seth Anderson
    Justin K. Owensby
    Rheumatology and Therapy, 2021, 8 : 599 - 607
  • [23] Frequency of Prescription Claims for Drugs that May Interact with Janus Kinase Inhibitors Among Patients with Rheumatoid Arthritis in the US
    Walton, Alison
    Paik, Jim
    Quebe, Amanda
    Kannowski, Carol L.
    Choong, Casey
    Anderson, Seth
    Owensby, Justin K.
    RHEUMATOLOGY AND THERAPY, 2021, 8 (01) : 599 - 607
  • [24] Efficacy and safety of different Janus kinase inhibitors combined with methotrexate for the treatment of rheumatoid arthritis: a single-center randomized trial
    Xiaoling Liao
    Wang Huo
    Wen Zeng
    Fang Qin
    Fei Dong
    Wanling Wei
    Ling Lei
    Advances in Rheumatology, 63
  • [25] Efficacy and safety of different Janus kinase inhibitors combined with methotrexate for the treatment of rheumatoid arthritis: a single-center randomized trial
    Liao, Xiaoling
    Huo, Wang
    Zeng, Wen
    Qin, Fang
    Dong, Fei
    Wei, Wanling
    Lei, Ling
    ADVANCES IN RHEUMATOLOGY, 2023, 63 (01)
  • [26] A comparison of Janus kinase inhibitor safety in rheumatoid arthritis
    Nash, Peter
    Lim, Irwin
    Marabani, Mona
    INTERNATIONAL JOURNAL OF RHEUMATIC DISEASES, 2021, 24 : 3 - 14
  • [27] Updates on efficacy and safety janus kinase inhibitors in juvenile dermatomyositis
    Kim, Hanna
    EXPERT REVIEW OF CLINICAL IMMUNOLOGY, 2024, 20 (06) : 589 - 602
  • [28] Crucial safety issues on Janus kinase inhibitors in rheumatoid arthritis might be associated with the lack of LDL-cholesterol management: a reasoned literature analysis
    Salvatore Corrao
    Internal and Emergency Medicine, 2023, 18 : 2157 - 2161
  • [29] Thromboembolism with Janus Kinase (JAK) Inhibitors for Rheumatoid Arthritis: How Real is the Risk?
    Scott, Ian C.
    Hider, Samantha L.
    Scott, David L.
    DRUG SAFETY, 2018, 41 (07) : 645 - 653
  • [30] Epigenetic targets of Janus kinase inhibitors are linked to genetic risks of rheumatoid arthritis
    Tsuchiya, Haruka
    Ota, Mineto
    Takahashi, Haruka
    Hatano, Hiroaki
    Ogawa, Megumi
    Nakajima, Sotaro
    Yoshihara, Risa
    Okamura, Tomohisa
    Sumitomo, Shuji
    Fujio, Keishi
    INFLAMMATION AND REGENERATION, 2024, 44 (01)
12345